156 related articles for article (PubMed ID: 23718933)
1. Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.
Smith B; Cohn DE; Clements A; Tierney BJ; Straughn JM
Gynecol Oncol; 2013 Sep; 130(3):416-20. PubMed ID: 23718933
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
Phippen NT; Leath CA; Chino JP; Jewell EL; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2012 Nov; 127(2):267-72. PubMed ID: 22892361
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
[TBL] [Abstract][Full Text] [Related]
4. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
Dueñas-González A; Zarbá JJ; Patel F; Alcedo JC; Beslija S; Casanova L; Pattaranutaporn P; Hameed S; Blair JM; Barraclough H; Orlando M
J Clin Oncol; 2011 May; 29(13):1678-85. PubMed ID: 21444871
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study.
Wang CC; Chou HH; Yang LY; Lin H; Liou WS; Tseng CW; Liu FY; Liou JD; Huang KG; Huang HJ; Huang EY; Chen CH; Chang TC; Chang CJ; Hong JH; Lai CH
Gynecol Oncol; 2015 Jun; 137(3):462-7. PubMed ID: 25827291
[TBL] [Abstract][Full Text] [Related]
6. Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial.
Dueňas-González A; Orlando M; Zhou Y; Quinlivan M; Barraclough H
Gynecol Oncol; 2012 Sep; 126(3):334-40. PubMed ID: 22691757
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
da Costa SCS; Bonadio RC; Gabrielli FCG; Aranha AS; Dias Genta MLN; Miranda VC; de Freitas D; Abdo Filho E; Ferreira PAO; Machado KK; Scaranti M; Carvalho HA; Estevez-Diz MDP
J Clin Oncol; 2019 Nov; 37(33):3124-3131. PubMed ID: 31449470
[TBL] [Abstract][Full Text] [Related]
8. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A
Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer.
de Azevedo CRAS; Thuler LCS; de Mello MJG; de Oliveira Lima JT; da Fonte ALF; Fontão DFS; Carneiro VCG; Chang TMC; Ferreira CG
Gynecol Oncol; 2017 Sep; 146(3):560-565. PubMed ID: 28709705
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
Roth JA; Carlson JJ
J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
[TBL] [Abstract][Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
15. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
16. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
Cihoric N; Tsikkinis A; Vlaskou Badra E; Glatzer M; Novak U; Scherz A; Shelan M; Soldatovic I; Yojena CKK; Aebersold DM; Lössl K
Radiat Oncol; 2017 Dec; 12(1):202. PubMed ID: 29273076
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Jin C; Zheng H; Zhan M; Wen F; Xu T
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
[TBL] [Abstract][Full Text] [Related]
18. Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial.
Nunes de Arruda F; da Costa S; Bonadio R; Dornellas A; Pereira D; de Bock GH; Del Pilar Estevez Diz M
Int J Gynecol Cancer; 2020 Jun; 30(6):749-756. PubMed ID: 32321767
[TBL] [Abstract][Full Text] [Related]
19. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
Gu MF; Liu LZ; He LJ; Yuan WX; Zhang R; Luo GY; Xu GL; Zhang HM; Yan CX; Li JJ
Int J Cancer; 2013 Jan; 132(1):215-23. PubMed ID: 22610788
[TBL] [Abstract][Full Text] [Related]
20. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Havrilesky LJ; Secord AA; Kulasingam S; Myers E
Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
